share_log

Xenon Pharmaceuticals Analyst Ratings

Xenon Pharmaceuticals Analyst Ratings

赛农制药分析师评级
Benzinga Analyst Ratings ·  2023/01/31 07:43
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 34.21% RBC Capital $49 → $51 Maintains Outperform
12/14/2022 57.89% Goldman Sachs → $60 Initiates Coverage On → Buy
12/12/2022 — Cowen & Co. Initiates Coverage On → Outperform
11/28/2022 31.58% Wells Fargo → $50 Initiates Coverage On → Overweight
11/11/2022 28.95% Guggenheim $53 → $49 Maintains Buy
10/19/2022 36.84% Raymond James → $52 Initiates Coverage On → Outperform
10/11/2022 28.95% RBC Capital $46 → $49 Maintains Outperform
08/29/2022 — B of A Securities Initiates Coverage On → Buy
08/11/2022 21.05% SVB Leerink $40 → $46 Maintains Outperform
08/10/2022 21.05% RBC Capital $41 → $46 Maintains Outperform
07/21/2022 44.74% JP Morgan → $55 Initiates Coverage On → Overweight
06/27/2022 7.89% Wedbush $47 → $41 Maintains Outperform
05/11/2022 7.89% RBC Capital $43 → $41 Maintains Outperform
11/11/2021 5.26% SVB Leerink $34 → $40 Maintains Outperform
10/28/2021 13.16% RBC Capital → $43 Initiates Coverage On → Outperform
10/04/2021 26.32% Needham $25 → $48 Maintains Buy
03/02/2021 -34.21% Needham $22 → $25 Maintains Buy
03/02/2021 -26.32% SVB Leerink $25 → $28 Maintains Outperform
10/02/2020 -42.11% SVB Leerink → $22 Initiates Coverage On → Outperform
07/21/2020 -42.11% Needham → $22 Initiates Coverage On → Buy
06/01/2020 -39.47% Jefferies $16 → $23 Assumes → Buy
03/25/2020 -39.47% Wedbush → $23 Initiates Coverage On → Outperform
01/08/2020 — William Blair Initiates Coverage On → Outperform
09/20/2019 -34.21% Guggenheim → $25 Initiates Coverage On → Buy
03/29/2019 — Stifel Assumes → Buy
08/08/2018 -60.53% Stifel $9 → $15 Maintains Buy
03/08/2018 -76.32% Stifel $7 → $9 Maintains Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
01/31/2023 34.21% 加拿大皇家银行资本 $49 → $51 维护 跑赢大盘
12/14/2022 57.89% 高盛 → $60 开始承保 →购买
12/12/2022 — 考恩公司 开始承保 →跑赢大盘
11/28/2022 31.58% 富国银行 → $50 开始承保 →超重
11/11/2022 28.95% 古根海姆 $53 → $49 维护 买
10/19/2022 36.84% 雷蒙德·詹姆斯 → $52 开始承保 →跑赢大盘
10/11/2022 28.95% 加拿大皇家银行资本 $46 → $49 维护 跑赢大盘
08/29/2022 — B of A证券 开始承保 →购买
08/11/2022 21.05% SVB Leerink $40 → $46 维护 跑赢大盘
08/10/2022 21.05% 加拿大皇家银行资本 $41 → $46 维护 跑赢大盘
07/21/2022 44.74% 摩根大通 → $55 开始承保 →超重
06/27/2022 7.89% 韦德布什 $47 → $41 维护 跑赢大盘
05/11/2022 7.89% 加拿大皇家银行资本 $43 → $41 维护 跑赢大盘
11/11/2021 5.26% SVB Leerink $34 → $40 维护 跑赢大盘
10/28/2021 13.16% 加拿大皇家银行资本 → $43 开始承保 →跑赢大盘
10/04/2021 26.32% 李约瑟 $25 → $48 维护 买
03/02/2021 -34.21% 李约瑟 $22 → $25 维护 买
03/02/2021 -26.32% SVB Leerink $25 → $28 维护 跑赢大盘
10/02/2020 -42.11% SVB Leerink → $22 开始承保 →跑赢大盘
07/21/2020 -42.11% 李约瑟 → $22 开始承保 →购买
06/01/2020 -39.47% 杰富瑞 $16 → $23 假设 →购买
03/25/2020 -39.47% 韦德布什 → $23 开始承保 →跑赢大盘
01/08/2020 — 威廉·布莱尔 开始承保 →跑赢大盘
09/20/2019 -34.21% 古根海姆 → $25 开始承保 →购买
03/29/2019 — Stifel 假设 →购买
08/08/2018 -60.53% Stifel $9 → $15 维护 买
03/08/2018 -76.32% Stifel $7 → $9 维护 买

What is the target price for Xenon Pharmaceuticals (XENE)?

氙气制药(Xene)的目标价是多少？

The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by RBC Capital on January 31, 2023. The analyst firm set a price target for $51.00 expecting XENE to rise to within 12 months (a possible 34.21% upside). 13 analyst firms have reported ratings in the last year.

加拿大皇家银行资本于2023年1月31日报道了氙气制药(纳斯达克代码：XENE)的最新目标价。这家分析公司将目标价定为51.00美元，预计Xene将在12个月内上涨(可能上涨34.21%)。过去一年，有13家分析公司公布了评级。

What is the most recent analyst rating for Xenon Pharmaceuticals (XENE)?

分析师对氙气制药(Xene)的最新评级是多少？

The latest analyst rating for Xenon Pharmaceuticals (NASDAQ: XENE) was provided by RBC Capital, and Xenon Pharmaceuticals maintained their outperform rating.

加拿大皇家银行资本提供了对氙气制药(纳斯达克代码：XENE)的最新分析师评级，氙气制药维持其表现优于大盘的评级。

When is the next analyst rating going to be posted or updated for Xenon Pharmaceuticals (XENE)?

氙气制药(Xene)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Xenon制药的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Xenon制药的上一次评级是在2023年1月31日提交的，所以你应该预计下一次评级将在2024年1月31日左右的某个时候公布。

Is the Analyst Rating Xenon Pharmaceuticals (XENE) correct?

分析师对Xenon制药(Xene)的评级正确吗？

While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a maintained with a price target of $49.00 to $51.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $38.00, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Xenon制药(Xene)评级维持不变，目标价在49.00美元至51.00美元之间。Xenon PharmPharmticals(Xene)目前的交易价格为38.00美元，超出了分析师的预测区间。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发